All News IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
13.45 ^SEK	-0.37%		-3.24%	+79.33%

Jul. 02	IRLAB Therapeutics AB Announces Phase IIb Study of Pirepemat Can Proceed as Planned After Positive Opinion from External Safety Committee	CI
May. 27	Sweden’s IRLAB Therapeutics Names New CEO	MT

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

IRLAB's Phase IIb study of pirepemat can proceed as planned after positive opinion from external safety committee	Jul. 02	AQ
IRLAB Therapeutics AB Announces Phase IIb Study of Pirepemat Can Proceed as Planned After Positive Opinion from External Safety Committee	Jul. 02	CI
IRLAB participates in Stora Aktiedagarna	Jun. 11	AQ
IRLAB appoints Kristina Torfgard as new CEO	May. 28	AQ
IRLAB presents at Redeye Growth Day 30 May	May. 28	AQ
Sweden’s IRLAB Therapeutics Names New CEO	May. 27	MT
IRLAB appoints Kristina Torfgård as new CEO	May. 27	AQ
IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024	May. 27	CI
IRLAB Therapeutics AB Strengthens Liquidity by Drawing SEK 25 Million on A Previously Secured Loan Facility	May. 23	CI
IRLAB strengthens its liquidity by drawing SEK 25 million on a previously secured loan facility	May. 23	AQ
Report from the Annual General Meeting 2024 of IRLAB Therapeutics AB	May. 22	AQ
IRLAB Therapeutics AB Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757	May. 22	CI
IRLAB has administered the first dose in a Phase I clinical trial with the drug candidate IRL757	May. 22	AQ
IRLAB broadcasts the annual general meeting live	May. 22	AQ
IRLAB presents at ABGSC Investor Days	May. 21	AQ
Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024	May. 08
IRLAB publishes interim report for the period January-March 2024	May. 08	AQ
IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	May. 07	CI
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy	May. 07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

All News

Filters